The Prognostic and Predictive role of DR70 immunoassay in Patients with Advanced (Metastatic) Breast Cancer.
| Autor: | Koca, Sinan, Babacan, Nalan Akgul, Okten, Ilker Nihat, Telli, Tugba Akin, Ala, Ozkan, Sezen, Bilge Aktas, Dane, Faysal, Yumuk, Perran Fulden |
|---|---|
| Předmět: |
BREAST cancer prognosis
BREAST tumor treatment KRUSKAL-Wallis Test RELATIVE medical risk PREDICTIVE tests CONFIDENCE intervals ONCOGENES LOG-rank test METASTASIS BLOOD collection POSITRON emission tomography computed tomography FISHER exact test MANN Whitney U Test IMMUNOASSAY CANCER patients PRE-tests & post-tests MOLECULAR biology COMPARATIVE studies PEARSON correlation (Statistics) TREATMENT effectiveness GLYCOPROTEINS DESCRIPTIVE statistics CHI-squared test KAPLAN-Meier estimator SYMPTOMS TUMOR markers TUMOR antigens STATISTICAL correlation DATA analysis software RECEIVER operating characteristic curves FIBRIN fibrinogen degradation products LONGITUDINAL method OVERALL survival PROPORTIONAL hazards models BREAST tumors EVALUATION |
| Zdroj: | Eurasian Journal of Medical Investigation; 2023, Vol. 7 Issue 2, p170-174, 5p |
| Abstrakt: | Objectives: DR-70 is a newly developed immunoassay that detects fibrin degradation products in blood. To the best of our knowledge, no previous study has investigated the prognostic and predictive value of DR-70 in patients with advanced breast cancer. Methods: Seventy-four metastatic breast cancer patients and 35 healthy volunteers were enrolled prospectively. Blood samples were collected before and after the treatment, and PET-CT imaging was performed accordingly. Results: The median age was 54 (range 27-89) years. N=47 (63.5%) were luminal breast cancer, n=20 (27%) were HER2 type, and n=7 (9.5%) were TNBC. The medianDR-70 levels of patients and healthy volunteers were significantly different 0.91(0.22-10) and 0.39(0.22-0.93) (p<0.001), respectively. There was no correlation between pre-treatment DR-70 and CEA, CA15-3 levels (p=0.68, p=0.43), respectively. The basal value of DR70 was not significant in predicting survival (p=0.29). A level of 55 % and above decrease in the DR70 values before and after treatment was found to be a good prognostic factor. There was A significant correlation between DR70 response and disease control (p<0.001). Conclusion: DR70 response is a good predictive marker for response evaluation and a good marker for prognostication In patients with advanced breast cancer. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|